 BOONTON, N.J., May 3, 2021 PRNewswire -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation Nasdaq: SWKH, today announced the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, providing custom solutions for the formulation, development and manufacturing of solid oral doses for difficult to formulate BCS III and IV compounds, including peptides and highly potent compounds. 